[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531803":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":22,"locations":28,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Comorbidities screening and management",null,[12],"Other: Screening and management of cormobidities",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Screening and management of cormobidities","During the routine care assessment and as part of the research, patients will :\n\n* Fill in cardiovascular risk assessment score: Life's simple 7\n* Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.\n\nAfter hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin\u002Fcreatinine ratio, protein\u002F urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days.",[9],[19],{"name":20,"affiliation":5,"role":21},"Camille ROUBILLE, MD","PRINCIPAL_INVESTIGATOR",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Fanny CARDON","CONTACT","0033 4 67 33 08 24","fanny-cardon@chu-montpellier.fr",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"University Hospital","RECRUITING","Montpellier","France","FR",{"type":36,"coordinates":37},"Point",[38,39],3.87635,43.61093,{"lat":39,"lon":38},[42,44],{"name":43,"role":25,"phone":10,"phoneExt":10,"email":10},"Camille ROUBILLE, DR",{"name":45,"role":21,"phone":10,"phoneExt":10,"email":10},"Camille ROUBILLE",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100531803","impact-of-assessment-and-management-of-comorbidities-in-internal-medicine-on-cardiovascular-risk-100531803",false,"NCT06204549","Impact of Assessment and Management of Comorbidities in Internal Medicine on Cardiovascular Risk","Impact du Bilan et de la Prise en Charge Des comorbidités en médecine Interne Sur le Risque Cardiovasculaire","COMMEDCARDIO","Inclusion Criteria:\n\n* High-Risk Cardiovascular patients either receiving:\n\n  * Primary prevention because they have never had a cardiovascular event but have several cardiovascular risk factors such as high blood pressure particularly resistant, metabolic syndrome, diabetes , dyslipidemia, metabolic steatosis\n  * Or secondary prevention because they have already had a major cardiovascular event such as ischemic heart disease, heart failure\n* Aged 18 and over\n* Patient benefiting from comorbidities assessment during their planned hospitalization in the internal medicine department.\n\nExclusion Criteria:\n\n* Patient refusal\n* Subject not registered in social security system\n* Pregnant or breastfeeding woman\n* Patient unable to give their informed consent, protected adult, vulnerable people\n* Subject deprived of liberty by judicial or administrative decision","ALL","18 Years",{"count":59,"type":60},70,"ESTIMATED","INTERVENTIONAL",[63],"NA","The aim of assessing and managing cardiovascular risk is to avoid, limit or delay cardiovascular morbidity and mortality. Planned internal medicine hospitalization is developed around the management of cardiovascular risk in patients at high cardiovascular risk, whether in primary prevention or secondary prevention.\n\nDuring planned hospitalization, patients benefit from comprehensive, personalized and adapted care for their comorbidities and their CVRF (cardiovascular risk factors).\n\nThis study will make it possible to evaluate this overall course of multidisciplinary management of comorbidities of patients at high cardiovascular risk.",[66,67],"Adverse Cardiac Event","Major Adverse Cardiac Events",[69,70],"Cardiovascular Risk","Comorbidities","2025-09-24",{"date":73,"type":74},"2025-09-30","ACTUAL",{"date":76,"type":74},"2024-05-21",{"date":78,"type":60},"2027-11-21",{"name":5,"class":6},1]